| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Androgen Antagonists | 75 | 2022 | 1412 | 8.230 |
Why?
|
| Prostatic Neoplasms | 161 | 2018 | 11101 | 8.190 |
Why?
|
| Gonadotropin-Releasing Hormone | 47 | 2015 | 1149 | 5.800 |
Why?
|
| Bone Neoplasms | 55 | 2019 | 2564 | 5.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 48 | 2017 | 1536 | 5.290 |
Why?
|
| Diphosphonates | 41 | 2016 | 634 | 4.690 |
Why?
|
| Bone Density Conservation Agents | 37 | 2016 | 797 | 4.500 |
Why?
|
| Leuprolide | 13 | 2015 | 313 | 2.960 |
Why?
|
| Orchiectomy | 29 | 2015 | 466 | 2.930 |
Why?
|
| Toremifene | 10 | 2013 | 24 | 2.900 |
Why?
|
| Imidazoles | 24 | 2016 | 1168 | 2.780 |
Why?
|
| Anilides | 13 | 2016 | 413 | 2.750 |
Why?
|
| Osteoporosis | 31 | 2012 | 1605 | 2.610 |
Why?
|
| Prostate-Specific Antigen | 36 | 2018 | 2463 | 2.020 |
Why?
|
| Phenylthiohydantoin | 5 | 2017 | 207 | 1.930 |
Why?
|
| RANK Ligand | 10 | 2013 | 321 | 1.730 |
Why?
|
| Prednisone | 15 | 2019 | 1567 | 1.440 |
Why?
|
| Bone Density | 28 | 2012 | 3573 | 1.430 |
Why?
|
| Antineoplastic Agents | 32 | 2022 | 13658 | 1.370 |
Why?
|
| Fractures, Bone | 19 | 2019 | 2062 | 1.280 |
Why?
|
| Neoplasms, Hormone-Dependent | 12 | 2014 | 409 | 1.260 |
Why?
|
| Thiohydantoins | 2 | 2018 | 19 | 1.150 |
Why?
|
| Osteoclasts | 9 | 2012 | 713 | 1.150 |
Why?
|
| Body Composition | 12 | 2014 | 2462 | 1.140 |
Why?
|
| Nitriles | 13 | 2017 | 980 | 1.110 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2016 | 123 | 1.080 |
Why?
|
| Goserelin | 5 | 2015 | 126 | 1.030 |
Why?
|
| Adenocarcinoma | 11 | 2014 | 6371 | 1.000 |
Why?
|
| Bone and Bones | 14 | 2014 | 2589 | 0.910 |
Why?
|
| Pyridines | 6 | 2016 | 2893 | 0.900 |
Why?
|
| Male | 196 | 2022 | 364641 | 0.870 |
Why?
|
| Tosyl Compounds | 7 | 2008 | 115 | 0.840 |
Why?
|
| Prostatectomy | 13 | 2016 | 1786 | 0.810 |
Why?
|
| Double-Blind Method | 27 | 2021 | 12464 | 0.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2022 | 11873 | 0.760 |
Why?
|
| Aged | 111 | 2021 | 171446 | 0.720 |
Why?
|
| Bone Diseases | 4 | 2010 | 416 | 0.710 |
Why?
|
| Aged, 80 and over | 58 | 2021 | 59598 | 0.690 |
Why?
|
| Castration | 4 | 2013 | 149 | 0.690 |
Why?
|
| Spinal Fractures | 3 | 2011 | 710 | 0.670 |
Why?
|
| Neoplasm Metastasis | 21 | 2019 | 4904 | 0.670 |
Why?
|
| Radium | 3 | 2019 | 70 | 0.660 |
Why?
|
| Androgens | 12 | 2022 | 1281 | 0.660 |
Why?
|
| Cardiovascular Diseases | 19 | 2015 | 15660 | 0.650 |
Why?
|
| Bone Remodeling | 8 | 2016 | 583 | 0.640 |
Why?
|
| Disease-Free Survival | 16 | 2018 | 6843 | 0.580 |
Why?
|
| Humans | 202 | 2022 | 767991 | 0.570 |
Why?
|
| Collagen Type I | 7 | 2016 | 618 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 9 | 2011 | 9252 | 0.560 |
Why?
|
| Diabetes Complications | 3 | 2013 | 1319 | 0.520 |
Why?
|
| Oligopeptides | 2 | 2011 | 1194 | 0.500 |
Why?
|
| Osteoblasts | 5 | 2013 | 1145 | 0.490 |
Why?
|
| Fractures, Spontaneous | 5 | 2015 | 232 | 0.490 |
Why?
|
| Pyrazoles | 2 | 2021 | 2028 | 0.480 |
Why?
|
| Flutamide | 4 | 2015 | 95 | 0.480 |
Why?
|
| Diabetes Mellitus | 8 | 2014 | 5887 | 0.480 |
Why?
|
| Neoplastic Cells, Circulating | 8 | 2016 | 952 | 0.470 |
Why?
|
| Middle Aged | 83 | 2021 | 223422 | 0.470 |
Why?
|
| Urogenital Neoplasms | 3 | 2012 | 130 | 0.460 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 1179 | 0.440 |
Why?
|
| Digital Rectal Examination | 2 | 2012 | 42 | 0.430 |
Why?
|
| Myostatin | 1 | 2014 | 129 | 0.420 |
Why?
|
| Insulin Resistance | 9 | 2013 | 3986 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2016 | 5694 | 0.400 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 287 | 0.400 |
Why?
|
| Disease Progression | 24 | 2017 | 13665 | 0.390 |
Why?
|
| Testosterone | 10 | 2017 | 2491 | 0.390 |
Why?
|
| Alkaline Phosphatase | 7 | 2014 | 863 | 0.380 |
Why?
|
| Prostate | 5 | 2015 | 1765 | 0.380 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 1942 | 0.370 |
Why?
|
| Benzamides | 5 | 2017 | 1377 | 0.360 |
Why?
|
| Treatment Outcome | 39 | 2017 | 65364 | 0.360 |
Why?
|
| Androstenes | 5 | 2015 | 177 | 0.350 |
Why?
|
| Kallikreins | 3 | 2017 | 219 | 0.350 |
Why?
|
| Sarcopenia | 2 | 2013 | 378 | 0.350 |
Why?
|
| Thiazolidinediones | 2 | 2004 | 460 | 0.350 |
Why?
|
| Peptides | 8 | 2016 | 4354 | 0.340 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1621 | 0.340 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2006 | 131 | 0.340 |
Why?
|
| Metabolic Diseases | 2 | 2014 | 684 | 0.330 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2014 | 411 | 0.330 |
Why?
|
| Absorptiometry, Photon | 5 | 2012 | 1758 | 0.330 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 662 | 0.330 |
Why?
|
| Taxoids | 8 | 2016 | 665 | 0.320 |
Why?
|
| Quality of Life | 6 | 2021 | 13489 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 563 | 0.310 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 861 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2016 | 9412 | 0.300 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 108 | 0.300 |
Why?
|
| Vaccines, DNA | 1 | 2009 | 279 | 0.300 |
Why?
|
| Body Mass Index | 6 | 2014 | 13053 | 0.300 |
Why?
|
| Pyrrolidines | 2 | 2006 | 340 | 0.280 |
Why?
|
| Veterans | 2 | 2012 | 2669 | 0.280 |
Why?
|
| Obesity | 6 | 2013 | 13091 | 0.270 |
Why?
|
| Androstadienes | 3 | 2013 | 348 | 0.270 |
Why?
|
| Clinical Trials as Topic | 12 | 2013 | 8052 | 0.270 |
Why?
|
| Steroids | 2 | 2012 | 938 | 0.260 |
Why?
|
| Injections, Subcutaneous | 3 | 2013 | 686 | 0.260 |
Why?
|
| Osteoblastoma | 1 | 2005 | 24 | 0.250 |
Why?
|
| Adipokines | 1 | 2008 | 309 | 0.250 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 3740 | 0.250 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 1804 | 0.250 |
Why?
|
| Incidence | 15 | 2015 | 21532 | 0.250 |
Why?
|
| Estramustine | 2 | 2005 | 35 | 0.240 |
Why?
|
| Metabolome | 1 | 2012 | 1009 | 0.240 |
Why?
|
| Survival Rate | 14 | 2016 | 12828 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6517 | 0.240 |
Why?
|
| Time Factors | 19 | 2017 | 40214 | 0.240 |
Why?
|
| Proportional Hazards Models | 13 | 2015 | 12536 | 0.230 |
Why?
|
| Placebos | 5 | 2014 | 1667 | 0.230 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 319 | 0.230 |
Why?
|
| Spinal Cord | 1 | 2012 | 1811 | 0.230 |
Why?
|
| Watchful Waiting | 3 | 2015 | 492 | 0.230 |
Why?
|
| Fatigue | 2 | 2008 | 1557 | 0.210 |
Why?
|
| Risk Factors | 22 | 2017 | 74936 | 0.200 |
Why?
|
| Signal Transduction | 4 | 2017 | 23642 | 0.200 |
Why?
|
| Lipids | 3 | 2008 | 3342 | 0.200 |
Why?
|
| Salvage Therapy | 3 | 2016 | 1273 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2012 | 12252 | 0.200 |
Why?
|
| Chromans | 1 | 2002 | 116 | 0.200 |
Why?
|
| Exercise Therapy | 1 | 2009 | 939 | 0.200 |
Why?
|
| Administration, Oral | 4 | 2017 | 4030 | 0.200 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 1736 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 878 | 0.190 |
Why?
|
| Adipose Tissue | 4 | 2014 | 3329 | 0.190 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 11221 | 0.190 |
Why?
|
| Endocrinology | 1 | 2007 | 443 | 0.180 |
Why?
|
| Prospective Studies | 17 | 2014 | 54924 | 0.180 |
Why?
|
| Follow-Up Studies | 15 | 2017 | 39345 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2004 | 617 | 0.180 |
Why?
|
| Indazoles | 1 | 2022 | 306 | 0.170 |
Why?
|
| SEER Program | 5 | 2014 | 1444 | 0.170 |
Why?
|
| Adult | 31 | 2022 | 223583 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2004 | 3187 | 0.170 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 4857 | 0.170 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2014 | 99 | 0.160 |
Why?
|
| Vinblastine | 1 | 2000 | 487 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4978 | 0.160 |
Why?
|
| Radiotherapy | 4 | 2011 | 1501 | 0.160 |
Why?
|
| Clodronic Acid | 2 | 2012 | 60 | 0.160 |
Why?
|
| Cholesterol | 1 | 2008 | 2914 | 0.160 |
Why?
|
| Kidney Neoplasms | 4 | 2012 | 4282 | 0.160 |
Why?
|
| Risk Assessment | 17 | 2012 | 24314 | 0.150 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 519 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 3553 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 6314 | 0.150 |
Why?
|
| Complementary Therapies | 2 | 2004 | 487 | 0.150 |
Why?
|
| Myocardial Infarction | 4 | 2012 | 11519 | 0.150 |
Why?
|
| Bone Resorption | 4 | 2010 | 728 | 0.150 |
Why?
|
| Prednisolone | 1 | 2019 | 326 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10470 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 3237 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2002 | 795 | 0.150 |
Why?
|
| Receptors, Androgen | 2 | 2015 | 1089 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7445 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2012 | 1567 | 0.140 |
Why?
|
| Odds Ratio | 5 | 2015 | 9666 | 0.140 |
Why?
|
| Prognosis | 12 | 2015 | 29979 | 0.140 |
Why?
|
| Triazoles | 1 | 2002 | 904 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2017 | 10396 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2006 | 1982 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2012 | 10098 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 12075 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5335 | 0.130 |
Why?
|
| Cohort Studies | 10 | 2016 | 41749 | 0.120 |
Why?
|
| Thiazoles | 1 | 2002 | 1542 | 0.120 |
Why?
|
| Body Weight | 2 | 2010 | 4628 | 0.120 |
Why?
|
| Radionuclide Imaging | 3 | 2014 | 2000 | 0.120 |
Why?
|
| Osteocalcin | 3 | 2008 | 275 | 0.110 |
Why?
|
| Gynecomastia | 1 | 2014 | 88 | 0.110 |
Why?
|
| Procollagen | 2 | 2011 | 189 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3726 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2004 | 12165 | 0.110 |
Why?
|
| Androstenols | 2 | 2010 | 25 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2006 | 2819 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 5394 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1667 | 0.110 |
Why?
|
| Carcinoma | 2 | 2016 | 2330 | 0.110 |
Why?
|
| Samarium | 1 | 2012 | 3 | 0.110 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2012 | 5 | 0.100 |
Why?
|
| Estradiol | 3 | 2007 | 1951 | 0.100 |
Why?
|
| Pyrroles | 3 | 2014 | 1123 | 0.100 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 98 | 0.100 |
Why?
|
| DNA Repair | 1 | 2022 | 2050 | 0.100 |
Why?
|
| Forecasting | 2 | 2016 | 2945 | 0.100 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2012 | 136 | 0.100 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2007 | 553 | 0.100 |
Why?
|
| United States | 15 | 2014 | 73027 | 0.100 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 76 | 0.100 |
Why?
|
| Retrospective Studies | 17 | 2017 | 81746 | 0.100 |
Why?
|
| Acid Phosphatase | 1 | 2011 | 141 | 0.100 |
Why?
|
| Comorbidity | 3 | 2012 | 10590 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3108 | 0.100 |
Why?
|
| Risk | 3 | 2014 | 9609 | 0.100 |
Why?
|
| Hot Flashes | 1 | 2014 | 330 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2015 | 724 | 0.090 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 124 | 0.090 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2004 | 146 | 0.090 |
Why?
|
| Femur | 2 | 2012 | 1321 | 0.090 |
Why?
|
| Indoles | 3 | 2014 | 1835 | 0.090 |
Why?
|
| Hip | 1 | 2012 | 256 | 0.090 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 872 | 0.090 |
Why?
|
| Algorithms | 2 | 2010 | 14163 | 0.090 |
Why?
|
| Depression | 2 | 2008 | 8231 | 0.090 |
Why?
|
| Calcium, Dietary | 2 | 2004 | 533 | 0.090 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 1326 | 0.080 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 398 | 0.080 |
Why?
|
| Haplotypes | 1 | 2016 | 2722 | 0.080 |
Why?
|
| Models, Biological | 2 | 2017 | 9493 | 0.080 |
Why?
|
| Breast Neoplasms | 8 | 2011 | 21206 | 0.080 |
Why?
|
| Leg | 1 | 2014 | 1088 | 0.080 |
Why?
|
| Hypogonadism | 2 | 2008 | 805 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1165 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 10757 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 1104 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2015 | 2166 | 0.070 |
Why?
|
| Fractures, Malunited | 1 | 2008 | 82 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 13499 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2011 | 1688 | 0.070 |
Why?
|
| Pain | 3 | 2014 | 5100 | 0.070 |
Why?
|
| Hyperaldosteronism | 1 | 2010 | 252 | 0.070 |
Why?
|
| Kinetics | 2 | 2015 | 6328 | 0.070 |
Why?
|
| Lumbar Vertebrae | 2 | 2009 | 1885 | 0.070 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 2227 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2863 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2014 | 2614 | 0.060 |
Why?
|
| Estrogens | 2 | 2003 | 1536 | 0.060 |
Why?
|
| DNA Damage | 1 | 2016 | 2470 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2008 | 246 | 0.060 |
Why?
|
| DNA, Antisense | 1 | 2005 | 44 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2010 | 797 | 0.060 |
Why?
|
| Neoplasms | 3 | 2009 | 22365 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2012 | 2660 | 0.060 |
Why?
|
| Coronary Disease | 2 | 2012 | 5919 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 709 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2007 | 2227 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2012 | 2428 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 2736 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2007 | 753 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4818 | 0.060 |
Why?
|
| Spine | 1 | 2012 | 1140 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2016 | 2908 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 1369 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2008 | 364 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 85 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2017 | 412 | 0.060 |
Why?
|
| Diagnostic Imaging | 3 | 2014 | 3532 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2014 | 2011 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 324 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 1904 | 0.050 |
Why?
|
| Cross-Sectional Studies | 5 | 2008 | 26375 | 0.050 |
Why?
|
| Age Factors | 3 | 2016 | 18407 | 0.050 |
Why?
|
| Ureteral Neoplasms | 1 | 2004 | 107 | 0.050 |
Why?
|
| Antimetabolites | 1 | 2003 | 128 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 15944 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2004 | 151 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2011 | 6339 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 1181 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 2908 | 0.050 |
Why?
|
| Female | 22 | 2016 | 397113 | 0.050 |
Why?
|
| Biopsy | 2 | 2011 | 6786 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2014 | 1531 | 0.050 |
Why?
|
| Edema | 1 | 2006 | 765 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1117 | 0.050 |
Why?
|
| Causality | 1 | 2008 | 1254 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2009 | 1288 | 0.050 |
Why?
|
| Cell Separation | 1 | 2007 | 1729 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 89155 | 0.050 |
Why?
|
| Multiple Myeloma | 3 | 2009 | 5196 | 0.050 |
Why?
|
| Serenoa | 1 | 2001 | 11 | 0.050 |
Why?
|
| Syndrome | 1 | 2008 | 3271 | 0.050 |
Why?
|
| Carboplatin | 1 | 2005 | 791 | 0.050 |
Why?
|
| Survivors | 2 | 2012 | 2381 | 0.050 |
Why?
|
| Alendronate | 1 | 2003 | 174 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2009 | 873 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 1820 | 0.050 |
Why?
|
| Flushing | 1 | 2001 | 52 | 0.050 |
Why?
|
| Hypericum | 1 | 2001 | 58 | 0.050 |
Why?
|
| Neutrophils | 1 | 2014 | 3786 | 0.050 |
Why?
|
| Anthropometry | 1 | 2006 | 1346 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2005 | 743 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2824 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2005 | 915 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2003 | 506 | 0.050 |
Why?
|
| Acupuncture | 1 | 2001 | 90 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1198 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 370 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 1304 | 0.040 |
Why?
|
| Triglycerides | 1 | 2008 | 2463 | 0.040 |
Why?
|
| Weight Gain | 1 | 2010 | 2359 | 0.040 |
Why?
|
| Animals | 6 | 2015 | 169222 | 0.040 |
Why?
|
| Coronary Artery Disease | 2 | 2010 | 6569 | 0.040 |
Why?
|
| Rats | 2 | 2008 | 23751 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 2008 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2004 | 887 | 0.040 |
Why?
|
| Thalidomide | 1 | 2005 | 886 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 1788 | 0.040 |
Why?
|
| Gene Expression | 1 | 2012 | 7597 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 1207 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 251 | 0.040 |
Why?
|
| Vitamin D | 1 | 2013 | 3311 | 0.040 |
Why?
|
| Pyrazines | 1 | 2005 | 1205 | 0.040 |
Why?
|
| Pelvic Bones | 1 | 2001 | 274 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 298 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5151 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1883 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 639 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 2403 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2002 | 8740 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14783 | 0.040 |
Why?
|
| Dyspnea | 1 | 2006 | 1352 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 14718 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 968 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2005 | 4748 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2010 | 2341 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5314 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 707 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2017 | 1642 | 0.040 |
Why?
|
| Health Promotion | 1 | 2010 | 2210 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8535 | 0.040 |
Why?
|
| Ketoconazole | 2 | 2010 | 95 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 3837 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2001 | 497 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 3966 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2012 | 2195 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 2001 | 516 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2002 | 879 | 0.030 |
Why?
|
| Erythropoietin | 1 | 2001 | 718 | 0.030 |
Why?
|
| Health Status | 1 | 2009 | 4092 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3858 | 0.030 |
Why?
|
| Cell Division | 1 | 2003 | 4473 | 0.030 |
Why?
|
| Collagen | 1 | 2004 | 2641 | 0.030 |
Why?
|
| Inflammation | 2 | 2014 | 10871 | 0.030 |
Why?
|
| Canada | 2 | 2013 | 2129 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 274 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2007 | 15442 | 0.030 |
Why?
|
| Food-Drug Interactions | 1 | 2014 | 26 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 2916 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 23 | 0.030 |
Why?
|
| Densitometry | 2 | 2004 | 151 | 0.030 |
Why?
|
| Morbidity | 2 | 2010 | 1754 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 4833 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 2107 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 389 | 0.030 |
Why?
|
| Boston | 1 | 2007 | 9368 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 598 | 0.030 |
Why?
|
| Cell Survival | 1 | 2003 | 5772 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2015 | 517 | 0.030 |
Why?
|
| Michigan | 1 | 2014 | 330 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2014 | 3583 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2003 | 2055 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2008 | 8540 | 0.030 |
Why?
|
| Disease Management | 1 | 2003 | 2533 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 381 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 794 | 0.020 |
Why?
|
| Radiography | 2 | 2014 | 6983 | 0.020 |
Why?
|
| Anemia | 1 | 2001 | 1514 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2001 | 1388 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 337 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 6606 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2006 | 6429 | 0.020 |
Why?
|
| Life Style | 1 | 2003 | 3932 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3813 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2015 | 905 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2599 | 0.020 |
Why?
|
| Urothelium | 1 | 2012 | 275 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9755 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2010 | 69 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 457 | 0.020 |
Why?
|
| California | 1 | 2014 | 1438 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 1265 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 590 | 0.020 |
Why?
|
| Calcium | 1 | 2003 | 5794 | 0.020 |
Why?
|
| Brachytherapy | 2 | 2010 | 1220 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2012 | 704 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 560 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1609 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 2871 | 0.020 |
Why?
|
| Mutation | 2 | 2016 | 30211 | 0.020 |
Why?
|
| Nomograms | 1 | 2010 | 236 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 111 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 101 | 0.020 |
Why?
|
| Osteoprotegerin | 1 | 2008 | 179 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 4261 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 17128 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2008 | 316 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3609 | 0.020 |
Why?
|
| Threonine | 1 | 2007 | 273 | 0.020 |
Why?
|
| Histidine | 1 | 2007 | 301 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2014 | 2001 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 3437 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2014 | 1068 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 547 | 0.020 |
Why?
|
| Proline | 1 | 2007 | 455 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2008 | 15831 | 0.020 |
Why?
|
| Prevalence | 1 | 2002 | 15867 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 1377 | 0.020 |
Why?
|
| Estradiol Congeners | 1 | 2004 | 22 | 0.010 |
Why?
|
| American Heart Association | 1 | 2010 | 1050 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2005 | 148 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1193 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2016 | 3140 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2010 | 1904 | 0.010 |
Why?
|
| Palliative Care | 2 | 2014 | 3642 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2007 | 1989 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 2429 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20757 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 2004 | 114 | 0.010 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 2543 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 1269 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2013 | 1951 | 0.010 |
Why?
|
| Tyrosine | 1 | 2007 | 1427 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4525 | 0.010 |
Why?
|
| Life Expectancy | 1 | 2010 | 1248 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7851 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2010 | 1188 | 0.010 |
Why?
|
| Finasteride | 1 | 2003 | 86 | 0.010 |
Why?
|
| Microfluidics | 1 | 2007 | 672 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2902 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 897 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3228 | 0.010 |
Why?
|
| Creatinine | 1 | 2007 | 1918 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 3514 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3623 | 0.010 |
Why?
|
| Age of Onset | 1 | 2007 | 3347 | 0.010 |
Why?
|
| Patient Selection | 1 | 2012 | 4258 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4114 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 1883 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 2592 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2007 | 22287 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3701 | 0.010 |
Why?
|
| Registries | 1 | 2014 | 8377 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 4938 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 1728 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2002 | 757 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 1493 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 8082 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 5458 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13289 | 0.010 |
Why?
|
| Kidney | 1 | 2004 | 7065 | 0.000 |
Why?
|
| Anticoagulants | 1 | 2004 | 4854 | 0.000 |
Why?
|
| Mice | 1 | 2015 | 82024 | 0.000 |
Why?
|
| Young Adult | 1 | 2014 | 60048 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 20218 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 18062 | 0.000 |
Why?
|